PEOPLE - ev3 makes appointments:
This article was originally published in Clinica
Executive Summary
Endovascular device maker, ev3 (Plymouth, Minnesota) has appointed Robert Palmisano as president, CEO and director; director Dan Levangie is named as chairman of the board. Together they replace James Corbett, who has resigned as president, CEO and chairman. Mr Palmisano joins from IntraLase (ophthalmic laser tech - acquired by Advanced Medical Optics in 2007), where he was president and CEO. Mr Levangie is on the board of Hologic (medical imaging), following its acquisition of Cytyc (2007) of which he was executive vice president, a member of the board and president of the surgical products division.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.